Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering

(2017) Melissa D. Barnes et al.   mBio

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.

(2016) Samuel L. Aitken et al.   CLINICAL INFECTIOUS DISEASES

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

(2015) Romney M. Humphries et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study

(2015) Nikhil P. Krishnan et al.   PLoS One

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09)

(2011) Mariana Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY